Reliance Life Sciences taps cancer drug market in India

September 23, 2013 3:50 am by Unnikrishnan, C.H.

MUMBAI -- Reliance Life Sciences Pvt. Ltd has introduced six anti-cancer drug brands in India, including a generic version of Swiss drugmaker Novartis AG's anti-blood cancer drug Glivec, as it seeks to tap the fast-growing market for oncology drugs in the country.

Read more: http://medcitynews.com/2013/09/reliance-life-sciences-taps-cancer-drug-market-india/#ixzz2fnylGOub

Greening the Valsartan Synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd « New Drug Approvals

Greening the Valsartan Synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd « New Drug Approvals:

'via Blog this'

Greening the Valsartan Synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd « New Drug Approvals

Greening the Valsartan Synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd « New Drug Approvals:

'via Blog this'

Nanomedicine » All About Drugs

Nanomedicine » All About Drugs:

'via Blog this'

Antibiotic Resistance » All About Drugs

Antibiotic Resistance » All About Drugs:

'via Blog this'

Combinatorial Chemistry in Drug Design « New Drug Approvals

Combinatorial Chemistry in Drug Design « New Drug Approvals:

'via Blog this'

Bioavailability « New Drug Approvals

Bioavailability « New Drug Approvals:

'via Blog this'